Newsletter Life Sciences Voice Top Five Newsletter

Life Sciences Voice Top Five Newsletter


Welcome to our latest edition of the Life Sciences Voice newsletter! In this issue, we bring you a roundup of important developments in the pharmaceutical and biotech industries. This week we take a look at Takeda withdrawing its dengue vaccine application, an almost $400M production deal between Samsung and Novartis, FDA’s safety concerns for Outset Medical’s hemodialysis treatment, and other top news!

Takeda Abandons Dengue Vaccine Application

Takeda has decided to withdraw its application for regulatory approval of QDengue, a dengue fever vaccine. The move comes after concerns were raised about the vaccine’s safety and effectiveness. Takeda plans to focus on conducting further clinical studies to address these concerns and meet regulatory requirements more comprehensively. Dengue fever is a global health concern, and Takeda aims to ensure the development of a safe and effective vaccine to combat this disease.

Opzelura Meets Eczema Trial Endpoint, Safety Concerns Persist

Opzelura, developed by Incyte, has successfully met its primary endpoint in a clinical trial for treating eczema. The drug demonstrated significant improvement in reducing skin inflammation and itchiness. However, safety concerns associated with the drug persist, as adverse events were reported in some patients, including serious infections. Incyte will continue evaluating the safety profile of Opzelura and work towards addressing these concerns to ensure the potential approval of the drug for eczema treatment.

Samsung’s $391M Deal with Novartis to Boost Production

Samsung has entered into a $391 million agreement with Novartis, as part of its plans to expand production capacity. The deal involves Samsung manufacturing pharmaceutical products for Novartis at its facilities in South Korea. This collaboration will help Novartis meet the growing demand for its medicines and improve supply chain efficiency. Samsung, known for its expertise in technology and manufacturing, aims to strengthen its position in the pharmaceutical contract manufacturing industry through strategic partnerships like this.

FDA Issues Warning to Outset Medical for its Tablo Hemodialysis System

The FDA has issued a warning letter concerning the Tablo Hemodialysis System by Outset Medical, a medical device used for hemodialysis treatment. The letter highlights several non-compliance issues identified during an inspection of the manufacturing facility. The FDA expressed concerns regarding the quality control processes, documentation practices, and corrective actions related to product failures. 

Opdivo Shows Promise in Phase 3 Bladder Cancer Trial

Opdivo, developed by Bristol Myers, has demonstrated positive results in a Phase 3 clinical trial for patients with advanced or metastatic bladder cancer. The study showed that Opdivo significantly improved overall survival compared to standard chemotherapy. Opdivo, an immune checkpoint inhibitor, has previously received approvals for various cancer indications. These latest findings offer hope for patients with bladder cancer, providing a potential new treatment option that may improve outcomes in this challenging disease.

Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you